Zevra Therapeutics, Inc. Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements
Zevra Therapeutics, Inc. (ZVRA) reported Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements of 0 shares for the 3-month period ending 2021-09-30, per its 10-Q filed 2021-11-10.
Discontinued › Notes › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements · last filed 2021-11-10
- Zevra Therapeutics, Inc. incremental common shares attributable to dilutive effect of share-based payment arrangements for the quarter ending 2021-09-30 was 0.00 shares.
- Zevra Therapeutics, Inc. incremental common shares attributable to dilutive effect of share-based payment arrangements for the quarter ending 2021-06-30 was 0.00 shares.
- Zevra Therapeutics, Inc. incremental common shares attributable to dilutive effect of share-based payment arrangements for the quarter ending 2020-09-30 was 0.00 shares.
- Zevra Therapeutics, Inc. incremental common shares attributable to dilutive effect of share-based payment arrangements for the quarter ending 2020-06-30 was 0.00 shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements 3 month | Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements 6 month | Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements 9 month |
|---|---|---|---|
| 2021-09-30 | 0.00 shares 10-Q · filed 2021-11-10 | 0.00 shares 10-Q · filed 2021-11-10 | |
| 2021-06-30 | 0.00 shares 10-Q · filed 2021-08-13 | 0.00 shares 10-Q · filed 2021-08-13 | |
| 2020-09-30 | 0.00 shares 10-Q · filed 2021-11-10 | 0.00 shares 10-Q · filed 2021-11-10 | |
| 2020-06-30 | 0.00 shares 10-Q · filed 2021-08-13 | 0.00 shares 10-Q · filed 2021-08-13 | |
| 2016-06-30 | 838.00K shares 10-Q · filed 2017-08-10 | 1.04M shares 10-Q · filed 2017-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |